top of page

Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib

On Oct 22, 2023, Dr. Jennifer Chan from Dana Farber Cancer Institute shared the CABINET trial data that showed cabozantinib (CABOMETYX®) helped those with advanced pancreatic NET and extrapancreatic NET (NET outside the pancreas). The results suggest that cabozantinib may be an effective option to treat NET patients, even those who have already tried other therapies. Exelis will discuss the results with the FDA. The NET patient community can be hopeful that there will likely be another FDA-approved oral treatment available in the near future.

Click here to read the detailed results of the CABINET trial here:

267 views0 comments

Recent Posts

See All


bottom of page